Supplier of Injectable Medications (Vials, Lyophilized Powders)

The contract seeks a supplier to provide injectable pharmaceuticals in single-dose vials, specifically lyophilized powders that require reconstitution prior to administration, for use in clinical research settings. These products must meet strict quality and stability standards suitable for investigational use, with packaging and labeling compliant with regulatory expectations for clinical trials. The effort is structured as a subcontract under the FDA Office of Acquisition and Grant Services, part of the Department of Health and Human Services, and is tied to the NAICS code 325412 for pharmaceutical preparation manufacturing. Responses are due by June 15, 2026, at 6:00 PM Eastern Time, following a posting date of May 4, 2026. The place of performance and detailed address are not specified, suggesting flexibility in logistics as long as delivery meets clinical trial timelines and regulatory requirements. There is no set-aside designation indicated, meaning all eligible suppliers may compete. The work supports the FDA’s role in advancing clinical research through reliable access to investigational medicinal products, with an emphasis on consistent supply, sterility, and proper formulation integrity to ensure the validity of clinical outcomes.